Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial.
Worawit LouthrenooSurasak NilganuwongRatanavadee NanagaraBoonjing SiripaitoonSabine Collaud BassetPublished in: Clinical rheumatology (2019)
ClinicalTrials.gov Identifier: NCT01264211 Key Points • Diacerein has shown positive effects on rheumatoid arthritis symptoms. • A good safety profile of diacerein has been observed when it was administered as add-on therapy to methotrexate in patients with rheumatoid arthritis.
Keyphrases
- rheumatoid arthritis
- placebo controlled
- double blind
- phase iii
- phase ii
- study protocol
- clinical trial
- disease activity
- high dose
- interstitial lung disease
- ankylosing spondylitis
- randomized controlled trial
- open label
- systemic lupus erythematosus
- stem cells
- low dose
- physical activity
- depressive symptoms
- squamous cell carcinoma
- bone marrow